投资快报 3

葉芬

ANX PRE-MART 狂起接近30%...
芬姐米哥,有什么意见?卖还是等$4...
SUNNY仔 发表于 6-1-2011 10:25 PM

有很大的機會拿到FDA的Approval哦。。要我是我會賣出部份，留一些等FDA-Approval。


FDA Accepts Exelbine(TM) NDA for Filing

Thu Jan 06 08:00:00 2011 EST
SAN DIEGO, Jan. 6, 2011 /PRNewswire via COMTEX News Network/ --

ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the U.S.
Food and Drug Administration (FDA) has accepted for filing the New Drug Application
(NDA) for its product candidate ANX-530 (vinorelbine injectable emulsion), or Exelbine.
The filing of the Exelbine NDA means the FDA has made a threshold determination
that it is sufficiently complete to permit a substantive review.
"We are pleased to have reached this important milestone, and look forward
to working with the FDA on moving Exelbine toward approval in 2011," said Brian
M. Culley, Chief Executive Officer of ADVENTRX.
About Exelbine
ADVENTRX is seeking approval of Exelbine for the same indications as Navelbine(R),
a branded formulation of vinorelbine, including non-small cell lung cancer. ADVENTRX
submitted the NDA as a 505(b)(2) application that relies in part on the FDA's findings
of safety and effectiveness of a reference drug. The Exelbine NDA includes data
from one clinical bioequivalence study designed to assess the pharmacokinetic equivalence
of Exelbine and Navelbine, the reference drug. In this clinical bioequivalence study,
Exelbine and the reference drug were determined by ADVENTRX to be bioequivalent.
ADVENTRX retains exclusive worldwide rights to Exelbine, other than in South
Korea, China, Hong Kong, Macau and Taiwan. In March 2010, the FDA conditionally
accepted "Exelbine" as the proposed proprietary name for ANX-530. The United
States Patent and Trademark Office has allowed patent claims related to Exelbine,
which claims will issue in January 2011 and expire in November 2027.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product
candidates are being developed to improve the performance of existing anti-cancer
drugs by addressing limitations associated principally with their safety and use.
More information can be found on the Company's web site at www.adventrx.com.
Forward Looking Statements
ADVENTRX cautions you that statements included in this press release that
are not a description of historical facts are forward-looking statements that are
based on ADVENTRX's current expectations and assumptions. Such forward-looking statements
include, but are not limited to, statements regarding regulatory approval of Exelbine
based on the 505(b)(2) NDA accepted for filing, working with the FDA in the regulatory
review process and the bioequivalence of Exelbine and Navelbine. Actual events or
results may differ materially from those expressed or implied by the forward-looking
statements in this press release due to a number of risks and uncertainties, including,
without limitation: the risk that ADVENTRX does not receive FDA approval of Exelbine
on a timely basis, or at all; the potential for the FDA to determine that the bioequivalence
data and other information included in the Exelbine NDA does not adequately support
bioequivalence with Navelbine, including as a result of performing pharmacokinetic
equivalence analyses based on a patient population other than the population on
which ADVENTRX based its analysis; the potential that changes made in transferring
the manufacturing process for Exelbine may result in a lack of comparability between
the commercial product and the material used in the bioequivalence trial; the risk
that results of future stability testing on samples of Exelbine do not support comparability
between ADVENTRX's prior and intended commercial manufacturing sites or a commercially-viable
expiration dating period; the potential for the FDA to impose other requirements
to be completed before or after approval of the Exelbine NDA, including that the
FDA may require ADVENTRX to perform additional nonclinical, bioequivalence or clinical
studies; ADVENTRX's reliance on third parties to assist with its bioequivalence
trials, regulatory submissions, manufacturing and other important aspects of the
Exelbine development program, and the risk that FDA approval may be delayed if their
performance is found to have been substandard; the risk that any patent issued to
ADVENTRX may not provide sufficient protection and market exclusivity for Exelbine
and may be challenged, invalidated, infringed or circumvented by third parties,
including by ADVENTRX's competitors; ADVENTRX's dependence on the success of Exelbine
as its first product candidate to be submitted for regulatory approval; the potential
that ADVENTRX may require substantial additional funding in order to obtain FDA
approval for and commercialize Exelbine, and the risk that ADVENTRX may not be able
to raise sufficient capital when needed, or at all; the potential for ADVENTRX to
enter into a commercial partnership or other strategic transaction relating to Exelbine
and that such partnership or transaction may not succeed in commercializing Exelbine;
and other risks and uncertainties more fully described in ADVENTRX's press releases
and periodic filings with the Securities and Exchange Commission. ADVENTRX's public
filings with the Securities and Exchange Commission are available at www.sec.gov.
You are cautioned not to place undue reliance on forward-looking statements,
which speak only as of the date when made. ADVENTRX does not intend to revise or
update any forward-looking statement set forth in this press release to reflect
events or circumstances arising after the date hereof, except as may be required
by law.
SOURCE  ADVENTRX Pharmaceuticals, Inc.

nigege

Dryship 为什么一开盘就飞？？昨天飞到一个程度，就调回很低。今天也会这样吗？

SUNNY仔

回复 2341# 葉芬


    ANX回落了...最低$3.03...

migo

回复 2343# SUNNY仔


    hdy 你又走宝了,看看下一个URRE会不会发疯!

SUNNY仔

回复 2344# migo


    套芬姐的话,机会多的是....

葉芬

回复  migo


    套芬姐的话,机会多的是....
SUNNY仔 发表于 7-1-2011 08:55 AM

   
對。機會永遠有。。。

葉芬

回复  SUNNY仔


    hdy 你又走宝了,看看下一个URRE会不会发疯!
migo 发表于 7-1-2011 02:53 AM

又要說聲恭喜 小弟，你的HDY時間抓得很準呢。

migo

回复 2347# 葉芬


    那要多谢芬姐!因为每次她有提到的股我都有留意 .可是我最近不大爱上CARI了,我拿你和SUNNY的电话和FACEBOOK,是我在洗厕所时方便大家能连在一起.一有动静随时随地能和大家一起注意!

migo

回复 2343# SUNNY仔


    SUNNY老弟,我在筹集一万资金买ANX.我挺你!够朋友了啦

SUNNY仔

回复 2348# migo


    哈哈..原来有人在美国帮忙看看市,互相帮助,互相合作是真的很方便的...

SUNNY仔

回复 2349# migo


    好!哪希望这几天ANX保持在几巴仙的上下幅度就OK了..等你搭上尾班车在起飞吧...

昨晚一上一下没了USD$五千多...

葉芬

回复  migo


    好!哪希望这几天ANX保持在几巴仙的上下幅度就OK了..等你搭上尾班车在起飞吧...  ...
SUNNY仔 发表于 7-1-2011 12:51 PM

    ANX 你已拿票的股，有時候是可以先賣後買回來賺差價。

葉芬

HDY 十六號的新聞。從現在至27號前還會有上升的機會。

Press Release Source: Hyperdynamics Corporation On Thursday December 16, 2010, 6:00 am EST

HOUSTON, Dec. 16, 2010 /PRNewswire/ -- Hyperdynamics Corporation (NYSE Amex: HDY) today announced that it signed a non binding Letter of Intent with a large independent oil and gas company and is in a period of exclusive negotiations until January 27, 2011, unless the parties agree otherwise, for a farmout of a portion of its interest in its concession offshore Guinea.

++++++++++++++++++++++


Overall Average: 96% Buy

Price        Support        Pivot Point        Resistance
6.13        5.15        5.89        6.63


+++++++++++++++++++++++++


三個月蠟燭圖表很漂亮。
特別是今次的走勢才剛開始第3天。

上次的漲勢走勢有9天及13天。

SUNNY仔

回复 2352# 葉芬


    就是一个"贪"字....结果错失了三次赚大钱的机会....我会紧记芬姐教诲的..

roberto

回复 2354# SUNNY仔

"贪"在股票市场是很正常的.....

我的XING就是不贪,赚USD100+, 结果第二晚少赚USD5K。

葉芬

回复  SUNNY仔

"贪"在股票市场是很正常的.....

我的XING就是不贪,赚USD100+, 结果第二晚少赚USD5K。 ...
roberto 发表于 7-1-2011 04:19 PM

呵呵 有賺就好。



很常都是這樣一賣就飛。

葉芬

回复  葉芬


    就是一个"贪"字....结果错失了三次赚大钱的机会....我会紧记芬姐教诲的..
SUNNY仔 发表于 7-1-2011 04:06 PM

下次有超過千元的賺幅就可以考慮先賣後買回。
不是說一定要賣完，可以玩部份。例如：有10粒，玩5粒，賺些利息也好。


要是有Chart來Support更好。

http://www.level2stockquotes.com/stock-charts.html

Live Stock Charts> 1min, 5min... etc..

SUNNY仔

回复 2355# roberto


    哪你应该是认同我了..

SUNNY仔

回复 2357# 葉芬


    芬姐的意思是.....我的SSN和ANX都要卖了是吗?....哈哈...
**SSN和ANX的赚幅都超过八钱美元了..

roberto

黄金掉，今晚PZG可能会有机会